Abstract：
Twenty-eight individuals who experienced proximal renal tubulopathy (PRT, Fanconi syndrome) while receiving tenofovir disoproxil initiated tenofovir alafenamide (TAF) and were followed for 5 years. None developed recurrent PRT or experienced significant changes in estimated glomerular filtration rate (by creatinine or cystatin-C), albuminuria, proteinuria, retinol-binding proteinuria, fractional excretion of phosphate, alkaline phosphatase, or bone mineral density at the lumbar spine. These data suggest that TAF is a well tolerated treatment option for individuals vulnerable to developing PRT.
摘要：
28例患有近端肾小管病的患者（PRT，范可尼综合征）在接受替诺福韦酯时开始替诺福韦艾拉酚胺（TAF）并随访5年。无一例发生复发性PRT或估计肾小球滤过率发生显著变化（根据肌酐或胱抑素C），白蛋白尿,蛋白尿,视黄醇结合性蛋白尿，磷酸盐的排泄分数，碱性磷酸酶,或腰椎的骨密度。这些数据表明，TAF对于易发生PRT的个体是一种耐受性良好的治疗选择。
